These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33833507)

  • 1. Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies.
    Hanania NA; Yohannes AM; Ozol-Godfrey A; Tocco M; Goodin T; Sharma S; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2021; 16():865-875. PubMed ID: 33833507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
    Tashkin DP; Ozol-Godfrey A; Sharma S; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2021; 16():945-955. PubMed ID: 33880019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
    Ohar JA; Ozol-Godfrey A; Goodin T; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2020; 15():995-1004. PubMed ID: 32440111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4.
    Ohar J; Tosiello R; Goodin T; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2019; 14():27-37. PubMed ID: 30587959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies.
    Donohue JF; Ozol-Godfrey A; Goodin T; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2020; 15():745-754. PubMed ID: 32341641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD.
    Putcha N; Ozol-Godfrey A; Sanjar S; Sharma S
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1061-1073. PubMed ID: 33907393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies.
    Ohar JA; Bowling A; Goodin T; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2019; 14():461-470. PubMed ID: 30863047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of glycopyrrolate/eFlow
    Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
    Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of background long-acting beta
    Kerwin EM; Tosiello R; Price B; Sanjar S; Goodin T
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2917-2929. PubMed ID: 30275690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
    Rajagopalan K; Bloudek L; Marvel J; Dembek C; Kavati A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies.
    Kerwin EM; Murray L; Niu X; Dembek C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2309-2318. PubMed ID: 33061349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies.
    Tashkin DP; Goodin T; Bowling A; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
    Respir Res; 2019 Jul; 20(1):135. PubMed ID: 31266489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of glycopyrrolate/eFlow
    Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
    Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
    Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
    Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
    LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
    Marin JM; Beeh KM; Clemens A; Castellani W; Schaper L; Saralaya D; Gunstone A; Casamor R; Kostikas K; Aalamian-Mattheis M
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1425-34. PubMed ID: 27418815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.
    Donohue JF; Bollu VK; Stull DE; Nelson LM; Williams VS; Stensland MD; Hanania NA
    Int J Chron Obstruct Pulmon Dis; 2018; 13():499-508. PubMed ID: 29440887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose selection for glycopyrrolate/eFlow
    Donohue JF; Goodin T; Tosiello R; Wheeler A
    Respir Res; 2017 Dec; 18(1):202. PubMed ID: 29202767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
    Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
    Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
    Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.